CliffBio
small molecule

TIGECYCLINE

TIGECYCLINE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameTIGECYCLINE
Active ingredientTIGECYCLINE
Strength50MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalDecember 2018
Marketing statusRX

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.